Outcomes for patients (LDAC vs LDAC + vosaroxin randomization). (A) AML LI-1: overall survival (no CR). (B) AML LI-1: overall survival from CR. (C) AML LI-1: survival from relapse. (D) AML LI-1: relapse-free survival. (E) AML LI-1: overall survival.